Enterprise Value

-25.75M

Cash

221.1M

Avg Qtr Burn

-33.91M

Short % of Float

5.68%

Insider Ownership

4.35%

Institutional Own.

89.56%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Lirentelimab (AK002) (Siglec-8) Details
Chronic urticaria

Big Mover™

Susp. Mover™

Phase 2b

Data readout

Lirentelimab (AK002) Details
Atopic dermatitis

Big Mover™

Susp. Mover™

Phase 2

Data readout

AK006 Details
Chronic urticaria

Phase 1

Initiation

Failed

Discontinued

Lirentelimab (AK002) (Siglec-8) Details
Eosinophilic Duodentitis , Eosinophilic Gastritis

Failed

Discontinued